<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04208815</url>
  </required_header>
  <id_info>
    <org_study_id>H19-122</org_study_id>
    <nct_id>NCT04208815</nct_id>
  </id_info>
  <brief_title>Evaluation of Dietary Milk Polar Lipids on Serum Cholesterol and Gut Microbiota in Healthy Adults</brief_title>
  <official_title>Evaluation of Dietary Milk Polar Lipids on Serum Cholesterol and Gut Microbiota in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Connecticut</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Connecticut</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine whether the daily consumption of 5 g of milk polar
      lipids influences serum lipids and gut microbiota composition in healthy adults.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Healthy adults will be recruited to participate in a randomized, single-blind, controlled,
      13-week crossover trial. Participants will follow a 2-week run-in control period consuming
      their habitual diets. Participants will then be randomized to consume 20 g of milk fat daily
      in the form of either a reconstituted milk polar lipid (MPL)-rich dairy beverage (MPL;
      providing 5.3 g MPL daily) or a control dairy beverage (CTL; providing 0.3 g MPL daily), each
      for 4- weeks, separated by a 3-week washout period. Participants will be instructed to
      consume intervention treatment/control beverages at breakfast (50 g) and dinner (50 g) and
      reconstitute the powders in water immediately prior to consumption. With the exception of the
      intervention beverages, participants will be asked to maintain their normal diet and exercise
      habits throughout the study. Venous blood will be collected after a 12-hour overnight fast
      into EDTA-coated (glucose analysis) and serum (lipid analyses) collection tubes. Passive
      drool and stool samples will be collected at the end of the run-in period (baseline) and
      intervention periods (treatment and control). Participants will be asked to complete a 5-day
      dietary record, food preference/liking/sedentary behavior surveys, and 7-day physical
      activity diary at the beginning and end of intervention periods.
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    COVID-19
  </why_stopped>
  <start_date type="Actual">March 1, 2020</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline Serum Total Cholesterol at 4 weeks</measure>
    <time_frame>4 weeks</time_frame>
    <description>Measurement of serum cholesterol (mg/dL) at the beginning and end of each 4-week intervention arms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Fecal Microbiota Shannon Index at 4 weeks</measure>
    <time_frame>4 weeks</time_frame>
    <description>Measurement of fecal microbiota Shannon Index at the end of each 4-week intervention arms.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Serum Cholesterol</condition>
  <condition>Gut Microbiome</condition>
  <arm_group>
    <arm_group_label>MPL-rich dairy beverage</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily consumption of 100 g of dairy powder containing 5.3 g MPL for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control dairy beverage</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Daily consumption of 100 g of dairy powder containing 0.3 g MPL for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Milk Polar Lipids</intervention_name>
    <description>Effects of the addition of 5 g of milk polar lipids to 20 g milk fat.</description>
    <arm_group_label>MPL-rich dairy beverage</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Milk Fat</intervention_name>
    <description>Effects of the addition of 20 g milk fat.</description>
    <arm_group_label>Control dairy beverage</arm_group_label>
    <arm_group_label>MPL-rich dairy beverage</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 18 to 50 years

          -  Body Mass Index &lt; 30 kg/m^2

          -  Willing to consume experimental intervention products on a daily basis

        Exclusion Criteria:

          -  Outside of age range (&lt;18 or &gt;50 years old)

          -  Body Mass Index &gt; 30 kg/m^2

          -  Triglycerides are higher than 500 mg/dL, glucose levels higher than 126 mg/dL, or
             total cholesterol higher than 240 mg/dL

          -  Self-reported history of renal or liver disease, diabetes, thyroid disease,
             gallbladder disease, eating disorders, heart disease, stroke, cancer and
             gut-associated pathologies

          -  Weight loss greater than 10% of body weight over preceding 4 weeks

          -  Taking probiotic supplements or oral antibiotics up to 1 month prior to the study and
             during the study

          -  Allergy to dairy or lactose intolerance

          -  Taking lipid-lowering medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Connecticut</name>
      <address>
        <city>Storrs</city>
        <state>Connecticut</state>
        <zip>06269</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>December 18, 2019</study_first_submitted>
  <study_first_submitted_qc>December 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 23, 2019</study_first_posted>
  <last_update_submitted>April 4, 2020</last_update_submitted>
  <last_update_submitted_qc>April 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Connecticut</investigator_affiliation>
    <investigator_full_name>Christopher Blesso</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Milk</keyword>
  <keyword>Polar Lipids</keyword>
  <keyword>Phospholipids</keyword>
  <keyword>Cholesterol</keyword>
  <keyword>Microbiota</keyword>
  <keyword>Microbiome</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

